We aim to assess the effect of standardized maternal anesthesia and surgery during pregnancy on the developing fetal brain in a rabbit model. Comparable to humans, the brain growth spurt in rabbits occurs in the perinatal period. STUDY DESIGN: 14 time-mated pregnant does (155 pups) underwent a laparotomy for 1.5h at day 28 of gestation (term¼31d). After induction with propofol, anesthesia was maintained with 4 vol-% sevoflurane for 2h . Maternal vital signs were continuously monitored (blood pressure, heart rate, peripheral and cerebral oxygen saturation, temperature, end-tidal CO 2 , pH, lactate). 7 does (74 pups), underwent invasive hemodynamic monitoring for 2h without sedation (sham). At term, does were delivered by cesarean section. Part of the pups underwent motoric and sensoric neurologic testing followed by euthanasia and brain histology at day 1. Other pups had daily neurodevelopment tests for 2 weeks and an extensive neurologic evaluation at 5 and 7 weeks (open field, object recognition test, T-maze and radial arm maze). RESULTS: Blood gases and vital parameters were stable during anesthesia. On postnatal day 1 surgery pups had significant lower motoric (25.0AE1.1 vs 23.2AE3.6;p¼0.004) and sensoric (16.7AE2.2 vs 15.0AE2.9;p¼0.005) neurobehavioral scores. Surgery pups were equal in weight but had smaller brains hence lower brain to body weight ratio (3.7%AE0.6 vs 3.4% AE0.6 ; p¼0.001). Neuron density was lower in multiple brain regions (e.g. hippocampus 2617AE410 vs 2053AE492 neurons/mm 2 ; p¼0.004) with lower proliferation rates and lower synaptic density. Daily testing showed delayed motoric development, e.g. hopping appearing later (6,4AE5,3 vs 12,3AE3,4 d; p¼0.011). By 7 weeks, no neurobehavioral differences were observed except for a reduced digging behavior (Table) . CONCLUSION: In rabbits, 2h maternal general anesthesia and laparotomy without fetal manipulation at d28 of gestation have a measurable impact on the term neonatal neurologic function and brain morphology. Pups develop slower but by 7 weeks, most of the differences faded out to become almost unrecognizable. OBJECTIVE: To determine whether metformin prevents the angiogenic imbalance and improves insulin sensitivity in an established model of obese mice with preeclampsia-like syndrome induced by overexpression of sFlt-1. STUDY DESIGN: CD-1 female mice were fed a high fat diet (HFD, 34.9%) for three months and then bred with CD-1 male mice. On day 1 of gestation (E1), the mice were randomized to receive either metformin 300mg/kg/day dissolved in drinking water (MET group, n¼6) or drinking water only (CTR group, n¼7). Mice remained on HFD throughout the pregnancy. On E9, mice from both groups were injected with adenovirus carrying sFlt-1 [AdFlt-1; 10
OBJECTIVE: To determine whether metformin prevents the angiogenic imbalance and improves insulin sensitivity in an established model of obese mice with preeclampsia-like syndrome induced by overexpression of sFlt-1. STUDY DESIGN: CD-1 female mice were fed a high fat diet (HFD, 34.9%) for three months and then bred with CD-1 male mice. On day 1 of gestation (E1), the mice were randomized to receive either metformin 300mg/kg/day dissolved in drinking water (MET group, n¼6) or drinking water only (CTR group, n¼7). Mice remained on HFD throughout the pregnancy. On E9, mice from both groups were injected with adenovirus carrying sFlt-1 [AdFlt-1; 10
9 PFU] via the tail vein. Blood pressure (BP) was measured on E7 and E17 using non-invasive tail cuff method. Fasting glucose (FG) was measured and serum was collected via tail vein before the HFD, after each month of the HFD, and on E7, E14 and E18. Mice were sacrificed on E18 and tissues were collected. sFLT-1, soluble endoglin (sENG) and insulin concentrations were determined using ELISA. The sFlt-1 and sENG results were normalized to E7 levels. FG and insulin were used to calculate HOMA-IR. Data was analyzed using t-test, One-Way and Repeated Measures ANOVAs with Sidak's multiple comparison as appropriate (statistical significance P < .05). RESULTS: There were no differences in dams weight, FG, insulin or HOMA-IR prior to pregnancy nor during pregnancy between the MET and CTR groups. Weight gain during pregnancy, dam and placental weight on E18 and numbers of pups and placentas were not different between the groups. Mean and systolic BP on E17 were significantly lower in the MET compared with CTR groups (P¼0.02 for both, Fig. 1 ). Moreover, sFlt-1 levels were significantly lower on E18 in the MET group compared with CTR group (P¼0.02, Fig. 2 ), however sENG levels were not different between the groups. CONCLUSION: Metformin significantly lowered BP and sFlt-1 levels in obese mice overexpressing sFlt-1. Our results add to the accumulating evidence indicating that trials of metformin treatment to prevent preeclampsia in obese women are warranted.
105 Regulatory dendritic cell treatment prevents the development of vasopressin-induced preeclampsia in mice 
OBJECTIVE:
The concept that poor fetal tolerance is important in the pathogenesis of preeclampsia (PE) has been demonstrated by our lab and others. Arginine vasopressin (AVP) infusion throughout pregnancy phenocopies human PE in mice mirroring the tonically elevated AVP secretion throughout human PE pregnancy. These findings identify AVP as a potential contributor to poor fetal tolerance and the development of PE. In addition to their conventional immuno-stimulatory role, dendritic cells (DCs) also play a vital role in immune tolerance. In contrast to conventional DCs, regulatory DCs (DCreg) promote tolerance via regulatory T cell induction, cellto-cell interactions, and anti-inflammatory cytokine production. The objective of this study is to determine if DCreg treatment will prevent PE in an AVP-induced mouse model of PE. STUDY DESIGN: C57BL/6 dams were infused with AVP (24 ng/hour) or saline throughout gestation via osmotic minipump. To generate DCreg, bone marrow derived cells from C57BL/6 mice were cultured with human TGFb1 and murine GM-CSF and IL-10. At the time of pump implantation (gestational day, GD -3) or early post-placentation on GD 7, AVP dams received a single intravenous injection of DCreg. Blood pressure was taken throughout pregnancy and total urine protein was measured on GD 18. Maternal tissues were collected on GD 18. Cytokine concentrations were determined via ELISA and normalized to total protein. RESULTS: Treatment of AVP-infused dams with DCreg before mating (GD -3) or on GD 7 prevented PE development. DCreg prevented hypertension (AVP: 120 AE1.8, n¼27 vs GD -3: 108 AE3.3, n¼7 vs GD 7: 110 AE4.4, n¼5 p<0.05) and elevations in proteinuria (AVP: 37.4 AE2.3, n¼24 vs GD -3: 25.6 AE2.9, n¼7 vs GD 7: 24.1 AE3.1, n¼5 p<0.05) (Figure 1 ). Elevations in pro-inflammatory plasma IFNg were reversed with treatment (AVP: 27.7 AE12.0, n¼6 vs GD -3: 0.0AE0.0, n¼4 vs GD 7: 0.0AE0.0, n¼6 pg/g, p<0.05) (Figure 2A ). DCreg also reversed suppression of anti-inflammatory TGFb in the plasma (AVP: 1.3 AE 0.91, n¼9 vs GD -3: 3.2 AE0.50, n¼4 vs GD 7: 2.9 AE0.25, n¼6 ug/g, p<0.05) ( Figure 2B ). CONCLUSION: These data support the hypothesis that DCreg treatment prevents AVP-induced PE. It further provides evidence for the potential use of personalized, cellular therapy in the prevention of cardiovascular, renal, and immune alterations induced by preeclampsia.
